Lynn Kramer

Lynn Kramer

Chief Clinical Officer, Deep Human Biology Learning (DHBL)

Eisai US•Westport, Connecticut, United States

View LinkedIn Profile
Experience19+ Years
LevelCXO

Executive Overview

Lynn D. Kramer, M.D., FAAN, is Chief Clinical Officer, DHBL (Deep Human Biology Learning) at Eisai and a member of the Eisai Co., Ltd. Executive Committee. In these roles, he oversees the product creation cycle, including clinical introduction and regulatory approval of innovative projects for all Eisai products. Dr. Kramer, who has been with Eisai since 2007, started as the Executive Vice President of Global Clinical Research, and was soon promoted to the additional role of Chief Operating Officer of Eisai Medical Research. In early 2009, he was named President of the Scientific and Operational Clinical Support Core Function Unit (SOCS CFU) and President of the Neuroscience, Product Creation Unit. He was named Chief Clinical Officer and a member of the Executive Committee, Eisai Company, Ltd. in 2012. In these functions he has been responsible for all functions including regulatory, biostatistics, data management, medical writing, clinical functions and clinical pharmacology and modeling and simulations. During this time, he has overseen the development and regulatory approval of several new molecular entities. Earlier in his career, he held senior positions in drug development including serving as Vice President Clinical Research and Head of the Therapeutic Area Strategy Team at Novartis, and Vice President Clinical Research at the R.W. Johnson Pharmaceutical Research Institute. Prior to his industry career he was Co-PI of an National Institutes of Health (NIH) sponsored epilepsy-focused program project in Los Angeles, California. Dr. Kramer is a Fellow of the American Board of Psychiatry and Neurology (1987) and the Philadelphia College of Physicians (1987). He previously served as the industry representative on the Peripheral and Central Nervous System Drugs Advisory Committee of the Food and Drug Administration (FDA) and on the Board of Directors at American Society for Experimental Neuro Therapeutics (ASENT). He currently is a member of the Pharma R&D Leadership Forum. In 2022, he became the 12th recipient of the 2022 Epilepsy Foundation’s Lifetime Accelerator Award. Dr. Kramer received his M.D. from Hahnemann Medical College. He completed his internship in internal medicine at the University of California at Irvine, and his residency in neurology at the University of Virginia.

Career Timeline

Professional employment history
  • Eisai USCurrent
    2007–Present· 19 yrs 9 mos
    • Chief Clinical Officer, Deep Human Biology LearningCurrent
      2007–Present
    • President Neuroscience and General Medicine Product Creation Unit
      Nov 2012–Jun 2025
  • Apr 2013–Jun 2025· 12 yrs 2 mos
    • Corporate Officer
      Apr 2013–Jun 2025
  • Jun 2009–Jun 2025· 16 yrs
    • President Neurosience Product Creation Unit
      Jun 2009–Jun 2025
  • May 2007–Jun 2009· 2 yrs 1 mo
    • Executive Vice President and Chief Operating Officer
      May 2007–Jun 2009

Education

Resident Neurology

University of Virginia

Intern in Medicine

UC Irvine

Doctor of Medicine - MD

Medicine

Hahnemann Medical College

Bachelor of Arts - BA

Multi/Interdisciplinary Studies

Lycoming College

Executive Relationship Map

Reports To
Lynn Kramer
Vice Chair & President
Chief Financial Officer
Chief Technology Officer
Chief Operating Officer

Executive Network Preview

BizKonnect has mapped this leadership network including reporting hierarchies, peer connections, and cross-functional relationships.

Verified Contact Information
Email & Direct Dial
Org Chart & Reporting Lines
Buying Committee Insights
AI-Powered Account Mapping

Skills & Expertise

12 of 12 skills
Drug DevelopmentProduct DevelopmentNeuroscienceGCPClinical DevelopmentClinical TrialsOncologyClinical ResearchInternal MedicineLife SciencesPharmaceutical IndustryBiotechnology